Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC for active idiopathic inflammatory myopathy
NL-OMON59049Phase 3Completed
- Sponsor
- argenx
- Start
- Mar 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM), polymyositis (PM) and 3 more comparing Efgartigimod PH20 SC plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Mean total improvement score at week 52. Started Mar 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)antisynthetase syndrome (ASSD)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NL-OMON59049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59049.